Ostenil 20mg 2ml hyaluronic acid 1% prefilled syringe joint injections osteoarthritis TRB Chemedica

Ostenil 20 mg 2 ml pre-filled syringe

Ostenil is a viscoelastic hyaluronic acid solution for the intra-articular treatment of osteoarthritis and degenerative joint diseases. The high molecular weight hyaluronic acid (2.0-3.0 MDa) restores the lubricating and shock absorbing properties of the synovial fluid.

Benefits for your patients

• Pain relief for osteoarthritis and degenerative joint diseases
• Improved joint function and mobility
• Targeted treatment of the affected joint
• Non-drug alternative to tablets and NSAIDs
• Long-lasting effect
• Clinically proven for over 20 years

What makes Ostenil unique?

• High molecular weight HA (2.0-3.0 MDa) for optimal viscoelastic properties
• CE-MDR certified according to the highest EU standards
• Clinically proven for mild to moderate osteoarthritis
• Ready-to-use prefilled syringe for easy application
• Over 20 years of experience in joint therapy

Product features

• Active ingredient: 10 mg/ml sodium hyaluronate (20 mg per 2 ml pre-filled syringe)
• Molecular weight: 2.0-3.0 million Daltons
• Application: Intra-articular, ready-to-use syringe
• Dosage: 1 injection of 2 ml per joint
• Sterile & pyrogen-free

Indications

Symptomatic treatment of degenerative joint diseases in osteoarthritis:

• Gonarthrosis (knee joint arthrosis)
• Osteoarthritis in the hip, shoulder and ankle joints
• Degenerative joint diseases with pain
• Mild to moderate osteoarthritis

Scope of delivery

• 1 sterile pre-filled syringe with 2 ml Ostenil (20 mg hyaluronic acid)
• Instructions for use
• CE declaration of conformity

Quality & Manufacturer

TRB Chemical – Specialist for viscoelastic solutions in orthopedics with many years of experience in the development of hyaluronic acid preparations.

Important note: Ostenil should only be administered by qualified healthcare professionals familiar with intra-articular injection. This product is intended for use by healthcare professionals only.